- Home
- CNTB vs ENTX Comparison
CNTB vs ENTX Comparison
Compare CNTB & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CNTB | ENTX |
|---|---|---|
| Founded | 2012 | 2010 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 128.6M | 142.0M |
| IPO Year | 2021 | 2018 |
Fundamental Metrics
Financial Performance| Metric | CNTB | ENTX |
|---|---|---|
| Price | $2.80 | $1.88 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | $8.50 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 152.2K | 138.9K |
| Earning Date | 02-14-2026 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $762,000.00 | $124,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $24,739.01 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 25.25 |
| 52 Week Low | $0.51 | $1.50 |
| 52 Week High | $3.28 | $3.22 |
Technical Indicators
Market Signals| Indicator | CNTB | ENTX |
|---|---|---|
| Relative Strength Index (RSI) | 61.08 | 41.80 |
| Support Level | $2.50 | $1.53 |
| Resistance Level | $2.89 | $2.04 |
| Average True Range (ATR) | 0.23 | 0.18 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 86.63 | 47.97 |
Price Performance
Historical ComparisonAbout CNTB Connect Biopharma Holdings Limited
Connect Biopharma Holdings Ltd is a clinical-stage company focused on the discovery and development of next-generation immune modulators for the treatment of serious autoimmune diseases and inflammation. It has leveraged its expertise in the biology of T cell modulation to build a portfolio of drug candidates consisting of small molecules and antibodies targeting critical pathways of inflammation. Its pipeline includes CBP-201, CBP-307 and CBP-174.
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.